Tag: non-hodgkin

FDA Grants Zanubrutinib an Accelerated Approval in MZL

The US Food and Drug Administration (FDA) has granted an accelerated approval to zanubrutinib (Brukinsa) for the treatment of adult patients with relapsed or refractory (R/R)...

CAR T-Cell Therapy Drives Refractory SLE Into Remission

Chimeric antigen receptor T-cell (CAR T) therapy, a life-extending treatment for patients with advanced B-cell malignancies and multiple myeloma, has now been shown to be...

Disturbing Number of Hospital Workers Still Unvaccinated

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Tim Oswalt had been in a Fort Worth, Texas, hospital for...

CAR T-cell Products Shine, Reveal New Insights

Real-world experience with chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas compares favorably with experience in commercial and trial settings and provides new...

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes

NEW YORK (Reuters Health) – Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection,...

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas

The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone...

First CAR T-cell Tx for Mantle Cell Lymphoma Fills Unmet Need

The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus)...

Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL

Giving steroids to patients with relapsed/refractory high-grade B-cell non-Hodgkin’s lymphoma (B-NHL) following chimeric antigen receptor (CAR) T-cell therapy may place them at substantially increased risk...

Cancer Rates on the Rise in Adolescents and Young Adults

Rates of cancer increased by 30% from 1973 to 2015 in adolescents and young adults (AYAs) (persons aged 15–39 years) in the United States, according...

B-cell Lymphoma Might Respond to N-myristoyltransferase Inhibition

NEW YORK (Reuters Health) – Targeting N-myristoylation might prove to be an effective treatment for B-cell lymphoma and other cancers, according to a preclinical study....

Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers

Risk factors for keratinocyte carcinomas, primarily pigment traits and sun sensitivity, were associated with the risk of developing non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia...

7 Things to Know About New Lymphoma Drug Tafasitamab

The US Food and Drug Administration (FDA) recently approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse...

Identifying Patients With Indolent Disease

Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow...

FDA Approves New Drug for Diffuse Large B-Cell Lymphoma

A novel drug, tafasitamab-cxix (Monjuvi, MorphoSys US Inc), has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients...

Rituximab Promising in New-Onset Myasthenia Gravis

Patients with myasthenia gravis (MG) who are treated early with the monoclonal antibody rituximab (multiple brands) achieve remission sooner than those treated later in the...